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InhibitorPhosphatidylcholine is the major lipid component of the malaria parasite membranes and is
required for parasite multiplication in human erythrocytes. Plasmodium falciparum
CTP:phosphocholine cytidylyltransferase (PfCCT) is the rate-limiting enzyme of the phosphatidyl-
choline biosynthesis pathway and thus considered as a potential antimalarial target. In contrast
to its mammalian orthologs, PfCCT contains a duplicated catalytic domain. Here, we show that both
domains are catalytically active with similar kinetic parameters. A virtual screening strategy
allowed the identiﬁcation of a drug-size molecule competitively inhibiting the enzyme. This com-
pound also prevented phosphatidylcholine biosynthesis in parasites and exerted an antimalarial
effect. This study constitutes the ﬁrst step towards a rationalized design of future new antimalarial
agents targeting PfCCT.
 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction deadly human malaria parasite. No efﬁcient vaccine is currentlyMalaria is a major global health problem with an estimated
annual 207 million cases and 627000 deaths, most of them chil-
dren under the age of 5 [1]. Plasmodium falciparum is the mostavailable and resistance to all available treatments has now been
observed [2]. Thus, the need for new antimalarial strategies involv-
ing novel targets and newmechanisms of action remains a priority.
During its intra-erythrocytic life cycle, P. falciparum relies on
phospholipids (PL) to build the membranes necessary for daugh-
ter cell development. The parasite possesses its own enzymatic
machinery to produce its main PL, phosphatidylcholine (PC) [3]
(Fig. 1A). We previously showed that choline analogs blocking
the entry of choline and the synthesis of PC in P. falciparum
led to parasite death [4,5]. Targeting PC synthesis in malaria
parasite is therefore a proven strategy. In P. falciparum, PC is
mostly synthesized by the Kennedy pathway and partially via
the conversion of phosphoethanolamine into phosphocholine
(P-choline) by a phosphoethanolamine N-methyltransferase, an
essential enzyme for malaria transmission [6–9] (Fig. 1A). In
both cases, the CTP:phosphocholine cytidylyltransferase (CCT)
[EC 2.7.7.15] is the rate-limiting enzyme. Generally, CCTs carry
a single catalytic domain followed by a membrane binding
domain and a region with phosphorylatable residues (Fig. 1B).
The catalytic domains of cytidylyltransferases are characterized
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Fig. 1. Phosphatidylcholine biosynthesis pathways in Plasmodium falciparum. (A) The precursor choline (Cho) is taken up from the host plasma by a choline carrier and the
new permeation pathways (NPP), both located in the red blood cell (RBC) membrane and by a parasite choline carrier that has not yet been identiﬁed. Choline is
phosphorylated by choline kinase (CK), phosphocholine (P-choline) is then activated by CTP:phosphocholine cytidylyltransferase (CCT) in presence of CTP. Finally, CDP-
choline is converted to phosphatidylcholine (PC) by the choline/ethanolamine-phosphotransferase (CEPT) in presence of di-acyl glycerol (DAG). In P. falciparum, PC can also be
obtained through a triple methylation of phosphoethanolamine (P-Etn) by phosphoethanolamine-methyltransferase (PMT). Enzymes are boxed in grey. (B) Comparison of
PfCCT and rat CCT domains. Both enzymes contain a catalytic domain (C) and a membrane binding domain (M). The positions of the CTP-binding motif HxGH and of the
cytidylyltransferase motif R(T/S)xG(V/I)STT are indicated by red horizontal bars in the domains C. In rat CCT, the membrane binding domain is followed by a region containing
phosphorylable residues (P).
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lyltransferase superfamily R(T/S)xG(V/I)STT (Figs. 1B and S1).
They associate to form homodimers through a conserved dimer-
ization motif R(Y/W)VD [10–12]. CCTs are amphitropic proteins,
operating a conversion between an inactive soluble state and an
active membrane-bound state [13,14]. The membrane binding
domain plays the role of a silencer in the soluble form and of
an activator in the membrane-bound form [10,15]. Removal of
the membrane binding segment from CCT proteins results in
constitutively active enzymes [16].
P. falciparum CCT is a 896 amino-acid protein with the unusual
feature of duplicated catalytic- and membrane-binding domains
(Fig. 1B). This duplication is found in three apicomplexan parasites,
Plasmodium, Babesia and Theileria but not in other eukaryotes [17].
The CTP-binding motif and the superfamily signature are con-
served in each PfCCT domain (Fig. S1). The N-terminal and C-term-
inal catalytic domains of PfCCT share 91% sequence identity over
180 amino-acids and 44% of sequence identity with the human
(and rat) CCT catalytic domain (Figs. 1B and S1). The dimerization
motif RWVD is also present in both PfCCT domains (residues 96–99
and 681–684). We recently reported that the C-terminal catalytic
domain of the recombinant PfCCT(528–795) forms a dimer [17]. In
the rodent malaria parasite Plasmodium berghei, the gene coding
for the CCT has been shown to be essential for parasite survival
[18]. So far, the enzymatic activity has been quantiﬁed in the para-
site [5] and only the C-terminal domain of PfCCT could be
expressed and characterized in vitro [17,19]. In the present work,
we biochemically characterized individually both PfCCT catalytic
domains and revealed that the two domains are active with similar
kinetic parameters. We investigated PfCCT druggability by model-
ing its three-dimensional structure and identiﬁed one drug-sized
molecule from a structure-based virtual screening. This compound
is the ﬁrst to function as a competitive inhibitor of the recombinantenzyme, to prevent PC biosynthesis and to exert an antimalarial
effect.
2. Materials and methods
2.1. Cloning, expression and puriﬁcation of recombinant PfCCT(1–210)
and PfCCT(528–795)
The PfCCT cDNA sequence (PlasmoDB: PF3D7_1316600) was
codon-optimized for expression in Escherichia coli (GenScript).
DNA sequences coding for PfCCT(1–210) and PfCCT(528–795) were
cloned in a pET15b expression vector (Novagen). Protein expres-
sion in E. coli BL21(DE3) was induced with 0.5 mM isopropyl b-D-
thiogalactopyranose for 24 h at 16 C in Luria–Bertani medium.
Bacteria were harvested by centrifugation at 6000g for 15 min at
4 C and stored at 80 C. Thawed cells were resuspended in
50 mM HEPES/NaOH pH 7, 400 mM NaCl for PfCCT(1–210) or
50 mM Tris/HCl pH 7.5, 100 mM NaCl for PfCCT(528–795), 2 mM b-
mercaptoethanol, 0.1% Triton X-100, 1 mg/ml lysozyme and an
EDTA free protease inhibitor cocktail (Roche). Bacteria were lysed
using a high-pressure homogenizer (French press) and the homo-
genate was clariﬁed by centrifugation at 40000g for 50 min. The
supernatant was applied onto a HisTrap HP column (GE
Healthcare) previously equilibrated with the corresponding above
mentioned buffers without Triton, lysozyme and EDTA. Both PfCCT
constructs were eluted with 500 mM imidazole after gradient steps
of 100 mM and 250 mM imidazole in the equilibration buffer. The
proteins fractions were concentrated with Amicon centrifugal ﬁl-
ters and further puriﬁed by gel-ﬁltration chromatography using a
HiLoad 16/60 Superdex 200 pg column (GE Healthcare) (Fig. S2).
Protein samples were eluted in 50 mM HEPES/NaOH pH 7,
400 mM NaCl, 2 mM b-mercaptoethanol for PfCCT(1–210) or
50 mM Tris/HCl pH 7.5, 100 mM NaCl, 2 mM b-mercaptoethanol
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corresponding to dimer and tetramer oligomerization states were
detected on the size-exclusion chromatography proﬁles (Fig. S2).
The fractions of the major peaks (dimers) were collected for further
characterization. The concentration of puriﬁed protein samples
was determined by absorbance measurements at 280 nm using a
Nanodrop 2000 spectophotometer (ThermoScientiﬁc).
2.2. Western blot and immunoﬂuorescence assays for subcellular
localization
To immunolocalize PfCCT in infected erythrocytes, parasites
cultures were ﬁxed for 4 h at room temperature in 4%
paraformaldehyde in PBS and incubated sequentially with an
anti-PfCCT antibody (1:200) obtained by immunization of mice
with PfCCT(617–769) and with secondary anti-(mouse IgG) Alexa
Fluor Red 594 antibodies (Fig. S3). Cells were mounted on slides
using Vectashield mounting medium containing DAPI (40,6-diami-
dino-2-phenylindole; Vector Laboratories). Parasites were
observed with a Zeiss Axioimager epiﬂuorescence microscope
equipped with Apotome (Carl Zeiss).
2.3. Steady-state and inhibition kinetic assays on recombinant enzyme
CCT activity of recombinant proteins was measured by follow-
ing the formation of CDP-choline from radiolabeled substrate
[14C]P-choline (American Radiolabeled Chemicals). Assays were
performed under optimal conditions in a ﬁnal volume of 50 ll con-
taining 100 mM HEPES/NaOH pH 7 for PfCCT(1–210) or 100 mM Tris/
HCl pH 8 for PfCCT(528–795), 20 mM MgCl2, from 75 lM to 10 mM
CTP, from 50 lM to 5 mM P-choline (0.4–40 lCi/lmol [14C]P-cho-
line) and 0.5 lg of puriﬁed protein. Reactions were carried out at
37 C for 10 min and were stopped by heating the mix at 99 C
for 5 min. A sample of 20 ll was spotted onto a thin layer chro-
matography silica-gel plate (Merck) pre-activated at 100 C for
1 h and separated using 98% ethanol/0.5% NaCl/30% ammonia
(50:50:1, v/v/v). Radioactive spots corresponding to CDP-choline
were visualized by Phosphorimager then scraped and quantiﬁed
by liquid scintillation spectrometry. Inhibition assays were per-
formed with substrate concentrations at their Km value and by
varying the compound concentration. Compounds were dissolved
in DMSO (ﬁnal DMSO < 1% v/v).
Kinetic data were ﬁtted with the Michaelis–Menten Eq. (1)
where v is the reaction rate (lM s1), Vmax is the maximum velocity
of the reaction (lM s1), [S] is the substrate concentration (lM)
and Km is the substrate concentration at which the reaction rate
is half of the maximum velocity. Inhibitor-dependent curves were
ﬁtted according to the competitive inhibition Eq. (2). The inhibition
constants Ki were determined from the global ﬁt of the data at
varying concentrations of inhibitor [i]:
m ¼ Vmax½S
Km þ ½S ð1Þ
m ¼ Vmax½S
Km 1þ ½iKi
 
þ ½S
ð2Þ
Inhibition effect was expressed as the compound concentration
inhibiting 50% of the enzyme activity (IC50). Substrate and inhibitor
dependent curves were analyzed with GraphPad Prism6.
2.4. Sequence alignment, model building and validation
Primary sequences of cytidylyltransferases were aligned using
MUSCLE [20] (Fig. S1). The structural models of the PfCCT
N-ter(8–189) and C-ter(581–779) domains were generated based onthe experimental structure of the catalytic domain of rat CCT
(PDB: 3HL4, residues 40–215) [21]. Modeller 9v8 was used to per-
form the comparative modeling of the intramolecular dimer form
[22]. Two lysine-rich regions corresponding to residues (132–
149) and (717–734), the linker (190–580) and the C-terminal
(780–896) regions were truncated as no reliable coordinates were
available for these parts. The product CDP-choline co-crystallized
with rat CCT was used as a constraint in Modeller to leave the cat-
alytic pocket open and to improve the accuracy of the model.
2.5. Virtual screening
A collection of about 8 million commercial compounds was
used for the virtual screening. The ﬁltering procedure was per-
formed by ligand-based followed by structure-based steps (see
Method S1 for details). Brieﬂy, a total of 117148 molecules were
selected by three ligand-based methods: 163 structural analogs
of CDP-choline retrieved for the similarity of their topological
extended connectivity ﬁngerprints with the CDP-choline template
[23]; 16307 molecules matching a pharmacophore model gener-
ated from the crystallized conformation of CDP-choline [24] and
100678 compounds ﬁtting the 3D shape and volume of the tem-
plate [25]. A docking secondary ﬁlter (structure-based step) using
the N-ter PfCCT 3D comparative model as target protein was per-
formed with the selected molecules. This structure-based screen-
ing reduced the number of candidates to 22072 molecules.
Finally, combining an automated selection based on deﬁned pro-
tein–ligand interactions (program LIGPLOT [26]) and careful
visual inspection, ten candidate compounds were selected
(Figs. 4 and S4). In parallel, one cytidyl- and three choline ana-
logs were selected by substructure similarity searching. The
PyMOL Molecular Graphics System (Version 1.5.0.4 Schrödinger,
LLC) was used for all molecular visualizations and image
rendering.
2.6. Assays for antimalarial activity
P. falciparum parasites (3D7 strain MRA102 from Malaria
Research and Reference Reagent Resource Center) were cultured
in O+ human red blood cells obtained from the local blood bank.
Antiplasmodial activity was routinely determined in microtiter
plates at 1.5% ﬁnal hematocrit and 0.6% parasitemia according to
a modiﬁed Desjardins test [27,28] based on [3H]hypoxanthine
incorporation into parasite nucleic acids after 48 h of incubation
in presence of the compound. [3H] hypoxanthine (0.6 lCi/well) in
30 ll of complete medium was added to each well of 200 ll of
parasite suspension and incubation was pursued for 18 h before
plates were frozen at 80 C. Cells were lysed by thawing and
the parasite DNA was recovered by harvesting the lysate on
glass-ﬁber ﬁlter plates (Uniﬁlter 96 GF/C; Perkin-Elmer) using a
FilterMate cell harvester (Packard Instruments). The antimalarial
activity of compounds was expressed as IC50 corresponding to
compound concentration leading to 50% inhibition of parasite
growth.
2.7. Inhibition of P. falciparum phosphatidylcholine biosynthesis
The inhibition of parasite PC and phosphatidylethanolamine
(PE) biosynthesis was evaluated in microtiter plates by measuring
the incorporation of radiolabeled [3H]choline (20 lM, 0.5 Ci/mmol)
or [3H]ethanolamine (2 lM, 4.2 Ci/mmol) into PC or PE. Infected
erythrocyte suspensions (2% hematocrit and 5% parasitemia) were
incubated in 150 ll of modiﬁed RPMI 1640 without choline and
supplemented with 25 mM HEPES/NaOH, pH 7.4 with or without
compound. After 30 min at 37 C, radiolabeled precursor (50 ll)
were added for a 3 h short incubation time to avoid toxic effects.
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Radiolabeled lipids were recovered and quantiﬁed as described in
Wein et al., [5]. The result expressed as IC50(PC) corresponded to
the compound concentration reducing the amount of synthesized
PC by 50%.
3. Results
3.1. Biochemical characterization and localization of PfCCT
PfCCT is atypical in having two catalytic domains resulting from
an ancestral duplication event. So far, the kinetic parameters have
only been determined for the C-terminal domain in a construct
encompassing the catalytic domain PfCCT(528–795) lacking a
lysine-rich region (residues 720–737) [17] and in a longer con-
struct comprising the membrane-binding domain PfCCT(528–896)
[19]. To comparatively investigate the enzymatic activity of both
domains, we designed two new PfCCT constructs for the N-ter
and C-ter catalytic domains, residues 1–210 and residues 528–
795, respectively. Each construct was expressed as recombinant
protein in E. coli and puriﬁed in a two-step protocol consisting of
Ni2+-afﬁnity chromatography followed by gel ﬁltration chro-
matography (Fig. S2). Puriﬁed PfCCT(1–210) and PfCCT(528–795) pro-
teins were obtained at ﬁnal concentrations of 0.6 mg/ml and
0.8 mg/ml, respectively. Enzymatic activities of both constructs fol-
lowed Michaelis–Menten kinetics with respect to both substratesFig. 2. Activity of recombinant PfCCT(1–210) and cellular localization in blood stage P
Representative Michaelis–Menten plots are shown with increasing concentration of p
substrate concentration. One representative experiment out of four is displayed in each c
are given in Table 1. (B) Western blot analysis of subcellular fractions of P. falciparum. Di
lysates was analyzed from synchronized parasites at the schizont stage. Lane 1, total
insoluble fraction (membranes). (C) Immunoﬂuorescence assays were performed on P. fa
antibody (red). Nuclei were stained in blue with DAPI.
Table 1
Kinetic parameters of the N-ter and C-ter PfCCT catalytic domains and of end
experiments.
Enzyme Substrate Km (mM)
PfCCT(1–210) Phosphocholine 1.10 ± 0.12
CTP 2.53 ± 0.62
PfCCT(528–795) Phosphocholine 2.47 ± 0.33
CTP 5.74 ± 0.37(Fig. 2A). Comparable kinetic parameters were found for the
N-ter(1–210) and C-ter(528–795) domains with similar Km and Vmax
values and kcat values of 2.96 ± 0.12 s1 and 2.45 ± 0.38 s1,
respectively (Table 1).
To better characterize the enzyme in the parasite, we raised
antibodies against the recombinant C-ter domain of PfCCT
(Fig. S3). Western blot analysis revealed a unique protein band at
the expected size in the lysate of Plasmodium infected red blood
cells (Fig. 2B). Upon sub-cellular fractionation, PfCCT was recov-
ered in both the cytosol and membrane fractions (Fig. 2B).
Immunoﬂuorescence assays showed the presence of the endoge-
nous PfCCT as a diffuse and dotted pattern (Fig. 2C). This suggested
that PfCCT is localized in the cytoplasm with possibly some regions
of higher concentration.
3.2. Comparative 3D model of PfCCT
In order to perform a structure-based screening on PfCCT and in
absence of an experimental 3D structure for this enzyme, we built
a comparative model of the PfCCT catalytic domains. The model
was based on the X-ray structure of the rat CCT crystallized in pres-
ence of CDP-choline (PBD: 3HL4). The 3D structural model of PfCCT
adopted an a/b fold and each catalytic domain formed a Rossmann
fold commonly found in nucleotide binding proteins (Fig. 3A). The
model suggested that the enzyme folded as an intramolecular
dimer, both catalytic domains being in contact (Fig. 3A). The. falciparum parasites. (A) Activity of recombinant PfCCT(1–210) catalytic domain.
hosphocholine (left panel) or CTP (right panel) while keeping constant the other
ase. Enzymatic parameters for both catalytic domains PfCCT(1–210) and PfCCT(528–795)
stribution of the endogenous PfCCT in the soluble and insoluble fractions of parasite
parasite extract (5  106 cells); lane 2, soluble fraction (parasite cytosol); lane 3,
lciparum infected red blood cells at the schizont stage and revealed by an anti-PfCCT
ogenous PfCCT. Values are the mean (±S.E.M.) of at least 3 independent
Vmax kcat (s1)
6.59 ± 0.27 (lmol/min/mg) 2.96 ± 0.12
4.46 ± 0.70 (lmol/min/mg) 2.45 ± 0.38
Fig. 3. Comparative model of PfCCT. (A) The backbone of PfCCT-N-ter and -C-ter (in blue) is superposed to the crystallographic structure of the rat CCT (PDB code 3HL4)
backbone (in green). The product CDP-choline (orange) has been docked in the N-ter PfCCT catalytic domain. (B) Close-view of the active site of the PfCCT-N-ter catalytic
domain. The hydrogen bonds between CDP-choline and the residues of the active site are shown in orange dashes. This 3D structure lacked the coordinates of the linker
region between the N-terminal and C-terminal catalytic domains.
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compared with template values (Table S1). All the residues
involved in the CDP-choline binding were conserved between the
N-ter and C-ter domains (Fig. 3B) and the superimposition of both
domains showed an identical overall fold (root-mean-square
deviation of 0.262 Å over 182 residues).
3.3. Selection of candidate inhibitors by virtual screening
Thermodynamic data used to assess the binding of substrates
and product of PfCCT(528–795) indicated that CDP-choline exhibited
a 3-fold higher afﬁnity for the enzyme than CTP while P-choline
binding could not be detected by isothermal titration calorimetry
[17]. Based on these data and in order to test PfCCT druggability,
we ﬁrst chose to select compounds mimicking CDP-choline by vir-
tual screening. A hierarchical screening strategy was adopted to
retrieve candidate inhibitors from a collection of about eight mil-
lion commercial compounds (Fig. 4). The screening collection
was ﬁrst ﬁltered according to the volume of the CCT active site
pocket (maximum volume of 700 Å3). Then three ligand-based
methods (molecular ﬁngerprints, pharmacophore searching and
3D shape similarity) were implemented based on the similarity
with the conformation of CDP-choline obtained from the rat
CCT–(CDP-choline) complex structure. Retained compounds were
further docked against the PfCCT-N-ter structural model. Ten can-
didates were selected from the ligand-based and the structure-
based virtual screenings (Figs. 4 and S4). In addition, a substructure
similarity search of each substrate selected one cytidyl- and three
choline analogs (Fig. S4).
3.4. Inhibition of recombinant PfCCT activity in vitro
The 14 compounds identiﬁed above were tested experimentally
for inhibition of CCT activity of both recombinant enzymes. Four
compounds were eliminated because of lack of stability or low
solubility in aqueous solution (Table S2). None of the substrate
analogs inhibited CCT activity up to 2 mM. The most efﬁcient hit
was compound 12 (C12), a product analog obtained by 3D shape
similarity searching. Its effect on PfCCT activity was comparablefor both the N-ter and the C-ter catalytic domains with IC50 of
641 lM and 820 lM, respectively (Fig. 5A). C12 was chosen for fur-
ther biochemical characterization. Complete inhibition could be
achieved in about one log scale concentration in a dose-dependent
manner (Fig. 5A). In comparison, the IC50 value of CDP-choline was
found to be 1.55 mM on the N-ter PfCCT domain (Fig. 5A and
Table S2). In order to decipher the mode of action of C12, we deter-
mined the type of inhibition. The double reciprocal representations
[1/V = f(1/[substrate]), where V is the velocity] showed that all lines
intersected on the 1/V axis indicating that C12 acted as a competi-
tive inhibitor of P-choline and CTP (Fig. 5B). Inhibition constants Ki,
obtained from non-linear regression of the Michaelis–Menten
equation, were found to be 870 lM and 423 lM with respect to
P-choline and CTP, respectively. These values are in the same range
as the IC50 values (determined at substrate concentrations equiva-
lent to Km values) and corroborated the competitive mode of
inhibition.
3.5. Antimalarial activity
In a second time, the compounds were evaluated for their effect
on parasite survival (Table S2). Again, C12 was the most efﬁcient
compound with an IC50 value of 42 lM (Fig. 6A and Table S2).
The inhibition of parasite growth thus occurred at substantial
lower concentration than the inhibition of the recombinant
enzyme activity. This discrepancy prompted us to investigate
the impact and the speciﬁcity of C12 on PC biosynthesis in
P. falciparum.
3.6. Effect of C12 on phosphatidylcholine biosynthesis in P. falciparum
We monitored newly synthesized PC and PE of P. falciparum-
infected erythrocytes by measuring the incorporation rate of
radiolabeled precursors. C12 had a complete and dose-dependent
inhibitory effect on cellular PC biosynthesis with an IC50(PC)
value of 187 lM (Fig. 6B). On the other hand, incorporation of
ethanolamine into PE was not signiﬁcantly affected up to 500 lM
of C12 (Fig. 6B). Our results clearly showed that PC biosynthesis
was affected prior to PE biosynthesis.
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As the rate-limiting enzyme of the PC biosynthesis pathway,
PfCCT represents an attractive antimalarial target. The present
study revealed that both domains of PfCCT are catalytically active
in contrast to PfCCT, the counterpart cytidylyltransferase of the
PE pathway that also possesses two cytidylyltransferase domains
but only the N-terminal one is active [29]. To our knowledge,
PfCCT is the ﬁrst studied enzyme of the cytidylyltransferase family
to bear two active domains. Other analyzed eukaryotic CCTs have asingle catalytic domain and fold as dimers. In the case of PfCCT, our
comparative 3D model suggested that the enzyme folds as an
intramolecular dimer. Studying the endogenous enzyme showed
that PfCCT was found in both the membrane and the soluble frac-
tions. This dual localization is consistent with the conversion that
CCT enzymes operate through their membrane binding domain
between an inactive soluble form and an active membrane-bound
form.
Due to the limited number of compounds that could be tested in
radiolabeled activity assay, a stringent computational screening of
A. Contet et al. / FEBS Letters 589 (2015) 992–1000 999commercial molecules mimicking CDP-choline was performed. It
has already been shown that CDP-choline acts as a competitive
inhibitor of the two substrates, CTP and P-choline [17]. The screen-
ing resulted in the selection of a molecule (C12) able to inhibit the
enzyme. C12 also exerted competitive inhibition with respect to
both substrates. This suggested that C12 occupied both substrate
sub-sites. Remarkably, the concentration needed to inhibit parasite
growth (IC50 = 42 lM) was about 15 times lower than the one to
inhibit PfCCT activity in vitro raising the question of a possible
off-target effect of C12 in vivo. Therefore, we investigated the effect
of C12 on de novo PC biosynthesis and showed that the compound
was capable to reduce PC production from choline with an IC50(PC)
of 187 lM while not affecting the synthesis of the other major
phospholipid PE. The 4-fold higher concentrations of C12 needed
to selectively inhibit PC synthesis with respect to the antimalarial
effect might possibly be explained by the differences in the time of
contact with the compound that is far shorter in the case of PC
biosynthesis (3 h) than in the case of the antimalarial assay
(48 h). Hypothetically, C12 might be accumulating in P. falciparum
like certain antimalarial drugs allowing the compound to reach an
inhibitory concentration for PfCCT [30–32]. Nevertheless, at this
point an off-target effect of C12 in vivo cannot be excluded. It’s also
conceivable that the following enzyme of the pathway, choline/
ethanolamine phosphotransferase is inhibited by C12 mimicking
its substrate. This hypothesis will have to be tested and if con-
ﬁrmed would allow a synergistic effect of C12 on two enzymes
of the PC pathway. Ability to affect more than one target can be
particularly important in delaying the emergence of drug resis-
tance. C12 is chemically tractable making it a good starting hit.
The binding mode of C12 in the catalytic pocket of the target has
been predicted (Fig. 7) and could be used to direct a rational con-
ception of more potent PfCCT inhibitors. Three hydrogen bonds
that would involve Val-40, His-124 and Thr-171 were found to
be analogous to the binding of CDP-choline to rat CCT [21]
(Fig. 7). But in comparison to CDP-choline, C12 would lack hydro-
gen bonds with Val-174, Lys-78, Tyr-129, Tyr-41, Asp-125 or His-
48, opening the route to improve hydrogen bond capability of
future analogs. Generating speciﬁcity of the compounds to PfCCT
versus human CCT will obviously be an important point for further
development. In this respect, a speciﬁc interaction with Gln51
(which is an Ala in human CCT) in the binding site could be
exploited (Fig. S1). Finally, we anticipate that more positive hits
will be found once a high-resolution crystal structure of PfCCT will
be available and a medium throughput non-radioactive enzyme
assay has been developed.
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